research Regulatory, Ethical, and Safety Considerations of Exosome‐Based Therapies in Dermatology
Exosome-based therapies in dermatology show promise but face challenges in standardization, regulation, and safety.
Search
forResearch
5 / 1000+ results
research International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women
Testosterone can help premenopausal and postmenopausal women with low sexual desire, but its long-term safety is unclear and it's not widely approved for this use.
research Ritlecitinib: First Approval
Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
research Japan Strengthens Regenerative Medicine Oversight
Japan improved its regulation of regenerative medicine to ensure safety and prevent unproven treatments.
research Part 2: LLLT Devices, Medical Device Regulation, and Impact on Development
Strict regulations may slow down new LLLT treatments.
Community Join
5 / 169 resultscommunity A warning to anyone considering 3rd party sourcing PP405 or its analogs
Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.
community swaping from 1mg fin to dut. how much mg would you guys recommend? taking 1mg fin now for a year but it still feels it's progressing a little bit.
Switching from 1mg finasteride to dutasteride, with users recommending starting at 0.5mg daily. Some users prefer capsules, while others use tablets, citing effectiveness and regulatory approval in Asia.
community Why is dutasteride approved for hair loss in Japan and South Korea but not for USA?
The reasoning for GSK's approval of dutasteride for hair loss in Japan and South Korea but not the US, with alternatives such as finasteride, minoxidil and RU58841 mentioned.
community Why doesn't phase 3 of PP405 start straight away?
Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.
community Breezula 6 Month Topline Phase III Results Released
Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.
Learn
5 / 801 resultslearn Rapamycin
mTOR regulator and immunosuppressant used more recently for anti-aging and hair regrowth
learn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
learn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
learn sh-Polypeptide-7
learn Overview
Experts
— no results
Clinics
— no results